Biogen’s Aducanumab Becomes First Drug Approved for Alzheimer’s in Nearly 20 Years Despite Controversy
XTalks
JUNE 9, 2021
Aducanumab Controversy and Price Tag. It’s hard to find a scientist, even one with ties to the manufacturer, who believes the totality of the evidence is persuasive,” he said in a Reuters article. Evidence for aducanumab’s efficacy has been highly contested. Currently, Alzheimer’s is the sixth leading cause of death in the US.
98 
Let's personalize your content